Intervention Protocol

Intravenous zoledronate for postmenopausal osteoporosis

  1. Ben-Hur Albergaria1,*,
  2. Brenda Nazaré Gomes Silva2,
  3. Álvaro N Atallah3,
  4. Virginia Fernandes Moça Trevisani4

Editorial Group: Cochrane Musculoskeletal Group

Published Online: 20 JAN 2010

DOI: 10.1002/14651858.CD008332

Database Title

Additional Information

How to Cite

Albergaria BH, Gomes Silva BN, Atallah ÁN, Fernandes Moça Trevisani V. Intravenous zoledronate for postmenopausal osteoporosis (Protocol). Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD008332. DOI: 10.1002/14651858.CD008332.

Author Information

  1. 1

    Federal University of Espirito Santo, Osteoporosis Diagnosis and Research Center (CEDOES), Victoria, Espirito Santo, Brazil

  2. 2

    The Brazilian Cochrane Centre, São Paulo, São Paulo, Brazil

  3. 3

    Universidade Federal de São Paulo / Escola Paulista de Medicina, Brazilian Cochrane Centre, São Paulo, SP, Brazil

  4. 4

    Universidade Federal de São Paulo, Rheumatology/Internal Medicine and Therapeutics, São Paulo, São Paulo, Brazil

*Ben-Hur Albergaria, Osteoporosis Diagnosis and Research Center (CEDOES), Federal University of Espirito Santo, Joao da Silva Abreu 78- Praia do Canto, Victoria, Espirito Santo, 29055 450, Brazil. benhur.gaz@terra.com.br.

Publication History

  1. Publication Status: New
  2. Published Online: 20 JAN 2010

SEARCH

ARTICLE TOOLS

View Full Article (HTML) Full (133K)
 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To determine the efficacy and safety of zoledronic acid therapy in the prevention and treatment of postmenopausal osteoporosis compared to placebo or active comparator (other bisphosphonates).

View Full Article (HTML) Full (133K)